RFA-NS-23-006: HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to small businesses. Applications closed on April 4, 2025.
From the official notice on Grants.gov, last changed September 15, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR43 / R44
- Clinical trialsNot allowed
- Funded byNINDS, NIAMS, NICHD
- Median yearly award$485,026
- Typical project length1.5 years
- R43, Small Business Innovation Research (SBIR) Phase I. A small business tests the feasibility of a technology or product. Other open R43 notices.
- R44, Small Business Innovation Research (SBIR) Phase II. Full research and development of an SBIR project after Phase I (or both phases at once, called Fast Track). Other open R44 notices.
Projects funded under RFA-NS-23-006 were run by National Institute of Neurological Disorders and Stroke (NINDS, 5 projects), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS, 2 projects), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, 2 projects) and National Center for Complementary and Integrative Health (NCCIH, 1 project), and 5 more. Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-NS-23-006 in the NIH Guide.
Key dates
| Posted | September 15, 2022 |
|---|---|
| Deadline | April 4, 2025 |
| Archived by Grants.gov | May 10, 2025 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Is this a realistic fit?
- Most of the money in the 13 programs behind this notice (74% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.
Funded under RFA-NS-23-006 so far
NIH funded 15 projects under RFA-NS-23-006 in fiscal 2023 to 2026, at 15 institutions. The median yearly award was $485,026.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Parmodulins without Abuse Potential for the Treatment of Neuropathic Pain | Function Therapeutics, Inc. | 2026 | $200,070 |
| Laboratory Developed Test (LDT) to Support Clinical Evaluation of a Drug for Painful Diabetic Neuropathy | Plumeria Therapeutics, Inc. | 2026 | $1.5 million |
| Wearable long duration postoperative topical cryotherapy for enhanced pain management | Cryo Ergonomics Inc | 2026 | $312,823 |
| Development of a novel, orally bioavailable, TAK1 inhibitor for the treatment of chemotherapy-induced peripheral neuropathy | Eydis Bio, Inc. | 2026 | $406,496 |
| Optogenetic Neuromodulation for Chronic Pain | Opsin Biotherapeutics Inc. | 2026 | $1.1 million |
| SN102: a Novel Gene Therapy for Trigeminal Neuralgia Pain | Sereneuro Therapeutics, Inc. | 2026 | $338,115 |
| Neural Ice Technology for Treatment of Pain | Brixton Biosciences, Inc. | 2025 | $1.0 million |
| PNM-CAP: A novel nerve cap to prevent painful neuroma formation in peripheral nerve injuries and amputations | Renerva, LLC | 2025 | $500,000 |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Who has won Cardiovascular Diseases Research grants before
From fiscal 2021 to 2025, Cardiovascular Diseases Research (93.837) awarded $15 billion across 11,798 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Trustees of the University of Pennsylvania | Pennsylvania | 313 | $380 million |
| Brigham & Womens Hospital Inc | Massachusetts | 274 | $374 million |
| Regents of the University of Michigan | Michigan | 277 | $355 million |
| The Trustees of Columbia University in the City of New York | New York | 207 | $335 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 295 | $320 million |
Who has won Biomedical Research and Research Training grants before
From fiscal 2021 to 2025, Biomedical Research and Research Training (93.859) awarded $15 billion across 11,631 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Leland Stanford Junior University | California | 186 | $290 million |
| Regents of the University of Michigan | Michigan | 226 | $268 million |
| University of California, San Diego | California | 198 | $264 million |
| Yale Univ | Connecticut | 195 | $250 million |
| University of Wisconsin System | Wisconsin | 169 | $241 million |
Other programs behind this notice
- Extramural Research Programs in the Neurosciences and Neurological Disorders
- Mental Health Research Grants
- Child Health and Human Development Extramural Research
- National Center for Advancing Translational Sciences
- Arthritis, Musculoskeletal and Skin Diseases Research
- Alcohol Research Programs
- Research Infrastructure Programs
- Research and Training in Complementary and Integrative Health
- Lung Diseases Research
- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-NS-23-006 still open?
No. It closed on April 4, 2025.
Who can apply for HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)?
Closed April 4, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-NS-23-006?
NIH RePORTER lists 15 projects funded under RFA-NS-23-006 in fiscal 2023 to 2026, at 15 institutions. The most were at Function Therapeutics, Inc., Plumeria Therapeutics, Inc., Cryo Ergonomics Inc.
Who has won Research and Training in Complementary and Integrative Health grants before?
The largest recipients over five fiscal years were Yale Univ, The General Hospital Corporation, Duke University. The program made 653 awards worth $575 million in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)